<DOC>
	<DOC>NCT00789828</DOC>
	<brief_summary>This study evaluated the efficacy and safety of Everolimus in treating patients with Subependymal Giant Cell Astrocytomas associated with Tuberous Sclerosis Complex.</brief_summary>
	<brief_title>Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Tuberous Sclerosis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>All Ages Definite diagnosis of Tuberous Sclerosis according to the modified Gomez criteria At least one Subependymal Giant Cell Astrocytoma of at least 1 cm in diameter Evidence of SEGA worsening as compared to prior MRI scans Females of child bearing potential must use birth control Written informed consent SEGA related surgery is likely to be required in the opinion of the investigator Recent heart attack, cardiac related chest pain or stroke Severely impaired lung function Severe liver dysfunction Severe kidney dysfunction Pregnancy or breast feeding Current infection History of organ transplant Surgery within two months prior to study enrollment Prior therapy with a medication in the same class as Everolimus Uncontrolled high cholesterol Uncontrolled diabetes HIV Patients with metal implants thus prohibiting MRI evaluations Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>SEGA</keyword>
	<keyword>Tuberous Sclerosis</keyword>
	<keyword>Subependymal Giant Cell Astrocytoma</keyword>
	<keyword>mTOR</keyword>
	<keyword>RAD001</keyword>
	<keyword>Mamalian Target Rapamycin</keyword>
	<keyword>Everolimus</keyword>
	<keyword>TSC</keyword>
</DOC>